IL206880A - An antibody that binds to Cadhrin-11 protein, its use for the preparation of a drug and an isolated nucleic acid encoded for antibody - Google Patents

An antibody that binds to Cadhrin-11 protein, its use for the preparation of a drug and an isolated nucleic acid encoded for antibody

Info

Publication number
IL206880A
IL206880A IL206880A IL20688010A IL206880A IL 206880 A IL206880 A IL 206880A IL 206880 A IL206880 A IL 206880A IL 20688010 A IL20688010 A IL 20688010A IL 206880 A IL206880 A IL 206880A
Authority
IL
Israel
Prior art keywords
antibody
cadherin
binds
medicament
protein
Prior art date
Application number
IL206880A
Other languages
English (en)
Hebrew (he)
Other versions
IL206880A0 (en
Original Assignee
Adheron Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adheron Therapeutics Inc filed Critical Adheron Therapeutics Inc
Publication of IL206880A0 publication Critical patent/IL206880A0/en
Publication of IL206880A publication Critical patent/IL206880A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL206880A 2008-01-11 2010-07-08 An antibody that binds to Cadhrin-11 protein, its use for the preparation of a drug and an isolated nucleic acid encoded for antibody IL206880A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1073408P 2008-01-11 2008-01-11
PCT/US2009/000162 WO2009089062A2 (en) 2008-01-11 2009-01-09 Cadherin-11 ecl domain antagonists for treating inflammatory joint disorders

Publications (2)

Publication Number Publication Date
IL206880A0 IL206880A0 (en) 2010-12-30
IL206880A true IL206880A (en) 2014-12-31

Family

ID=40602259

Family Applications (1)

Application Number Title Priority Date Filing Date
IL206880A IL206880A (en) 2008-01-11 2010-07-08 An antibody that binds to Cadhrin-11 protein, its use for the preparation of a drug and an isolated nucleic acid encoded for antibody

Country Status (15)

Country Link
US (4) US8591888B2 (enExample)
EP (2) EP3181588A1 (enExample)
JP (1) JP5511684B2 (enExample)
CN (1) CN101952316B (enExample)
AU (1) AU2009204467B2 (enExample)
BR (1) BRPI0906492A2 (enExample)
CA (1) CA2711394A1 (enExample)
DK (1) DK2242769T3 (enExample)
ES (1) ES2611102T3 (enExample)
HU (1) HUE031207T2 (enExample)
IL (1) IL206880A (enExample)
MX (1) MX2010007551A (enExample)
PL (1) PL2242769T3 (enExample)
SI (1) SI2242769T1 (enExample)
WO (1) WO2009089062A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010007551A (es) * 2008-01-11 2010-11-30 Synovex Corp Antagonistas de la cadherina-11 y metodos para el tratamiento de trastornos inflamatorios de las articulacion.
EP3138915A1 (en) * 2010-05-04 2017-03-08 The Brigham and Women's Hospital, Inc. Detection and treatment of fibrosis
US8877188B2 (en) 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis
BR112013001062A2 (pt) * 2010-07-15 2016-05-24 Synovex Corp anticorpos humanizados que visam o domínio ec1 de caderina-11 e composições e métodos relacionados
CA2865972C (en) 2012-02-29 2022-01-04 Pulmatrix, Inc. Inhalable dry powders
KR20130142025A (ko) * 2012-06-18 2013-12-27 한국생명공학연구원 카드헤린―１１ 단백질의 발현 또는 활성 억제제를 포함하는 대장암 치료 또는 전이 억제용 약학적 조성물
WO2016100301A1 (en) 2014-12-15 2016-06-23 The Brigham And Women's Hospital, Inc. Use of cadherin-11 antagonists to treat obesity-associated conditions and other metabolic disorders
US10435452B2 (en) 2015-05-29 2019-10-08 Children's Hospital Medical Center Cadherin 26 (CDH26)-Fc fusion proteins and methods of use thereof to treat inflammatory conditions
KR101654526B1 (ko) * 2015-10-19 2016-09-06 한국생명공학연구원 카드헤린―１１ 단백질의 발현 또는 활성 억제제를 포함하는 대장암 치료 또는 전이 억제용 약학적 조성물
EP3402572B1 (en) 2016-01-13 2022-03-16 Children's Hospital Medical Center Compositions and methods for treating allergic inflammatory conditions
US11859250B1 (en) 2018-02-23 2024-01-02 Children's Hospital Medical Center Methods for treating eosinophilic esophagitis
EP3781588B1 (en) 2018-04-20 2024-10-30 Children's Hospital Medical Center Blood biomarker for eosinophilic gastrointestinal disorders
US12297501B2 (en) 2019-02-25 2025-05-13 Children's Hospital Medical Center Methods for diagnosing and treating eosinophilic gastritis

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US253200A (en) * 1882-02-07 Timothy guilford
US215482A (en) * 1879-05-20 Improvement in spring be d-bottoms
US229811A (en) * 1880-07-13 dtjnlop
US248219A (en) * 1881-10-11 Panorama-toy
US248220A (en) * 1881-10-11 Machine for graining and dicing leather
US110755A (en) * 1871-01-03 Improvement in spike-machines
US229199A (en) * 1880-06-22 Wood-working machine
US8323A (en) * 1851-08-26 colne
US96746A (en) * 1869-11-09 Improvement in mechanical movements
US4172124A (en) 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
WO1987001130A1 (en) 1985-08-15 1987-02-26 Stauffer Chemical Company Tryptophan producing microorganism
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
DE59109269D1 (de) 1990-06-28 2005-12-15 Hoechst Ag Fusionsproteine mit Immunglobulinanteilen, ihre Herstellung und Verwendung
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5440021A (en) 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
CU22584A1 (es) 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
US5859136A (en) * 1997-11-03 1999-01-12 E. I. Du Pont De Nemours And Company Coating composition containing an amine functional dispersed polymer and an isocyanate curing agent
US6638911B1 (en) 1998-05-05 2003-10-28 Adherex Technologies Inc. Compounds and methods for modulating desmosomal cadherin-mediated functions
US7481999B2 (en) 1998-05-05 2009-01-27 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin-mediated function
US6472367B1 (en) 1998-05-05 2002-10-29 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin mediated cell adhesion
AU759144B2 (en) * 1998-05-05 2003-04-03 Adherex Technologies Inc. Compounds and methods for modulating nonclassical cadherin-mediated functions
US6680175B2 (en) 1998-05-05 2004-01-20 Adherex Technologies, Inc. Methods for diagnosing and evaluating cancer
US6787136B1 (en) * 1999-09-03 2004-09-07 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
ES2592507T3 (es) 1999-09-03 2016-11-30 The Brigham And Women's Hospital, Inc. Métodos y composiciones para el tratamiento de enfermedad inflamatoria mediante el uso de agentes moduladores de cadherina-11
US20040110755A1 (en) * 2002-08-13 2004-06-10 Boehringer Ingelheim Pharmaceuticals, Inc. Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions
AU2003298475A1 (en) * 2002-11-14 2004-06-18 Adherex Technologies, Inc. Compounds and methods for modulating desmosomal and atypical cadherin-mediated cell adhesion
US6952969B2 (en) * 2003-09-30 2005-10-11 The Aerospace Corporation Ceramic ball bearing fracture test method
WO2006089397A1 (en) * 2005-02-22 2006-08-31 Gemin X Biotechnologies Inc. Methods for treating arthritis using triheterocyclic compounds
MX2010007551A (es) 2008-01-11 2010-11-30 Synovex Corp Antagonistas de la cadherina-11 y metodos para el tratamiento de trastornos inflamatorios de las articulacion.
CN101998966A (zh) 2008-02-11 2011-03-30 诺瓦提斯公司 使用钙黏着蛋白11(cdh11)拮抗剂的方法
CN102753579A (zh) * 2009-05-01 2012-10-24 国立大学法人东京大学 抗钙粘着蛋白抗体
BR112013001062A2 (pt) 2010-07-15 2016-05-24 Synovex Corp anticorpos humanizados que visam o domínio ec1 de caderina-11 e composições e métodos relacionados

Also Published As

Publication number Publication date
JP5511684B2 (ja) 2014-06-04
EP3181588A1 (en) 2017-06-21
AU2009204467A1 (en) 2009-07-16
SI2242769T1 (sl) 2017-02-28
CN101952316B (zh) 2015-04-01
US20140120104A1 (en) 2014-05-01
EP2242769A2 (en) 2010-10-27
WO2009089062A2 (en) 2009-07-16
EP2242769B1 (en) 2016-11-02
DK2242769T3 (en) 2017-02-06
WO2009089062A3 (en) 2009-09-24
BRPI0906492A2 (pt) 2015-12-01
US9315568B2 (en) 2016-04-19
HUE031207T2 (hu) 2017-07-28
CN101952316A (zh) 2011-01-19
ES2611102T3 (es) 2017-05-04
MX2010007551A (es) 2010-11-30
WO2009089062A8 (en) 2010-09-02
US7972846B2 (en) 2011-07-05
US20110045003A1 (en) 2011-02-24
PL2242769T3 (pl) 2017-06-30
IL206880A0 (en) 2010-12-30
US20110008323A1 (en) 2011-01-13
JP2011509094A (ja) 2011-03-24
US8591888B2 (en) 2013-11-26
AU2009204467B2 (en) 2012-09-06
CA2711394A1 (en) 2009-07-16
US20090253200A1 (en) 2009-10-08

Similar Documents

Publication Publication Date Title
IL206880A (en) An antibody that binds to Cadhrin-11 protein, its use for the preparation of a drug and an isolated nucleic acid encoded for antibody
ES2873253T3 (es) Leptinas altamente solubles
US9085637B2 (en) Selective PYY compounds and uses thereof
CN108026153B (zh) 作为选择性肽双重glp-1/胰高血糖素受体激动剂的新毒蜥外泌肽-4衍生物
US10005824B2 (en) Selective PYY compounds and uses thereof
ES2732475T3 (es) Polipéptidos modificados por ingeniería genética que tienen una duración potenciada de la acción y una inmunogenicidad reducida
JP6621752B2 (ja) 変異した線維芽細胞増殖因子（ｆｇｆ）１および使用方法
US8841249B2 (en) Growth hormones with prolonged in-vivo efficacy
US10583172B2 (en) HPYY(1-36) having a beta-homoarginine substitution at position 35
TW201833132A (zh) 作為肽類ｇｌｐ１／升糖素／ｇｉｐ三重受體激動劑之新穎化合物
TW201833131A (zh) 作為胜肽類ｇｌｐ１／升糖素／ｇｉｐ受體促效劑之新化合物
TW201127397A (en) Growth hormones with prolonged in-vivo efficacy
JP2008530245A5 (enExample)
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
CN105727261A (zh) 包含弹性蛋白样肽的治疗剂
EA200702093A1 (ru) Антитела-миметики glp-1 человека, композиции, способы и их применение
CA3093386A1 (en) Toxin-derived delivery constructs for oral delivery
RU2012123642A (ru) Аналоги инсулина, содержащие хлорированные аминокислоты
NZ627888A (en) Materials and methods for respiratory disease control in canines
CN102652831A (zh) 生物膜的免疫治疗
EP2174951A3 (en) Mutant of granulocyte-colony stimulating factor (G-CSF) and chemically conjugated polypeptide thereof
JP5529014B2 (ja) 部位特異的なペグ化をされた直鎖状のサケカルシトニン類似体
DE60135650D1 (de) Amidotransferase und dessen expressionsprodukt
KR20010024805A (ko) 베타-리포트로핀 및 그의 용도
JP2007517775A5 (enExample)

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees